Patient characteristics and treatment patterns in patients with advanced or recurrent endometrial cancer in Europe: A real-world study (348)

Abstract

<b>Objectives:</b> Endometrial cancer (EC) is the fourth most common cancer among women in developed countries. Understanding regarding the characteristics of and the post-platinum treatment (tx) profile for women with advanced/recurrent (A/R) EC is limited. The objective of this study was to describe real-world patient (pt) demographics, clinical characteristics, tx patterns, and outcomes in European pts with A/R EC. <b>Methods:</b> This retrospective chart review study utilized data collected from European pts (Germany, France, Spain, Italy, UK) with EC from the IQVIA Oncology Advantage Database. A <i>de novo</i> case report form captured relevant variables for pts receiving tx after initial platinum-based regimens for A/R EC. Pts were included if they had progressed on ≤2 prior lines of chemotherapy (CT) with ≥1 prior platinum-based chemotherapy regimen. For pts receiving active tx (vs hormone monotherapy or best supportive care) after chemotherapy, the index date was the date of initiation of the post-platinum tx. For pts not receiving active post-platinum tx, the index date was the discontinuation date of the last therapy or the date of progression. Pts were included if their index date was between January 1, 2013, and December 31, 2016. Pts were followed from their index date to the last visit, the record of death, or the date of data extraction from September to November 2020 (whichever came first). Mismatch repair (MMR)/microsatellite instability (MSI) status was collected. Tx response, defined as complete or partial response (CR/PR), was identified as per RECIST v1.1 or provider assessment. <b>Results:</b> A total of 339 pts were included. Pts were treated by 227 providers (>33 providers in each country), with 56% in a teach- ing/university hospital setting. Mean (SD) age at A/R EC diagnosis was 60.3 (9.1) years and 61.4 (9.2) years at index date. An Eastern Cooperative Oncology Group performance status of 1 at index date was reported for 91% of pts. MMR/MSI status was tested in 108 pts (32%); 16% (17/108) were MMR deficient/MSI-high. During the follow-up period, 214 pts (63%) died; 207 (97%) deaths were due to EC. The most common index (i.e., first active post-platinum) tx were doxorubicin monotherapy (21%), paclitaxel monotherapy (11%), and carboplatin/paclitaxel (7%); 20% did not receive active tx after the index date. In the 271-pts receiving active tx, the most common reasons for stopping index tx included tx completion (35%; 95/271) or distant progression/relapse (22%; 59/271). The response rate to index tx in pts receiving active tx was 44% (120/271), including 20% (54/271) with the best response of a CR and 24% (66/271) with a PR; 24% (65/271) had stable disease. Among all pts (<i>n</i>=339), only 8% received further active tx after index tx/care, commonly paclitaxel (2.4%), topotecan (1.8%), and doxorubicin (1.2%). <b>Conclusions:</b> These results showed that pts with A/R EC received variable active tx following platinum-based chemotherapy. <b>Funding</b>: GSK (213506). Editorial support provided by Fishawack Indicia, part of Fishawack Health, funded by GSK.